Vaginectomy (Vaginal Resection) in India and UAE | Complete Patient Guide

• ONCOLOGIC INDICATIONS: Histologically confirmed vaginal carcinoma (FIGO Stage I–II), recurrent cervical or endometrial cancer involving the vaginal wall, vaginal intraepithelial neoplasia (VAIN III) unresponsive to laser ablation or topical 5-fluorouracil, and clear cell adenocarcinoma in DES-exposed individuals.

• RECONSTRUCTIVE / FUNCTIONAL INDICATIONS: Severe vaginal stenosis or obliteration following prior pelvic radiation, complex rectovaginal or vesicovaginal fistulae not amenable to repair, and congenital vaginal anomalies requiring anatomical revision.

• GENDER-AFFIRMING SURGERY: Transmasculine patients undergoing total hysterectomy with colpectomy (vaginectomy) as part of phalloplasty or metoidioplasty preparation; patients must have documented gender dysphoria per WPATH SOC-8 criteria and completed hormonal therapy as appropriate.

• REQUIRED PRE-OPERATIVE DIAGNOSTICS: MRI pelvis with gadolinium (mandatory — defines tumour depth, parametrial involvement, and proximity to bladder/rectum); PET-CT scan (for oncologic staging — detects nodal and distant metastases); colposcopy and directed biopsy (histologic confirmation); cystoscopy and proctoscopy (if anterior or posterior vaginal wall involvement is suspected); complete blood count, coagulation profile (PT/INR/aPTT), renal and liver function tests, HbA1c (if diabetic); ECG and 2D echocardiogram (for patients over 50 or with cardiac history); HPV genotyping and cytology (for VAIN-related cases).

• RELATIVE CONTRAINDICATIONS: Distant metastatic disease (Stage IVB) where curative surgery is not feasible; severe cardiopulmonary comorbidity precluding general or regional anaesthesia (ASA Class IV–V); uncorrected coagulopathy; active pelvic infection; patient refusal of blood transfusion without available bloodless surgery protocol.

• ABSOLUTE CONTRAINDICATIONS: Unresectable disease on pre-operative imaging with no reconstructive margin achievable; patient unwilling to accept the functional consequences of total vaginectomy after comprehensive counselling.

STANDARD OPEN (RADICAL) VAGINECTOMY:

Performed via a combined abdominal and perineal approach, this technique provides the widest surgical field and is preferred for bulky tumours, cases requiring pelvic lymph node dissection, or when concurrent pelvic exenteration is planned. The vaginal cuff, parametrial tissue, and — in radical procedures — the upper two-thirds to entire vaginal canal are excised en bloc. Reconstruction using a rectus abdominis myocutaneous (RAM) flap or gracilis flap is performed at the same sitting to restore pelvic floor integrity and create a neovagina if desired. Blood loss is higher than minimally invasive approaches (median 400–800 mL); hospital stay is typically 7–10 days.

LAPAROSCOPIC VAGINECTOMY:

A four-port laparoscopic technique enables upper vaginal resection with pelvic lymphadenectomy in selected patients (FIGO Stage I, upper-third lesions). Carbon dioxide pneumoperitoneum (12–15 mmHg) with 30° Trendelenburg positioning optimises visualisation of the pararectal and paravesical spaces. Blood loss is reduced (median 150–300 mL), hospital stay averages 4–6 days, and return to normal activity occurs at 3–4 weeks. Limitations include reduced tactile feedback and longer operative time for complex reconstruction.

ROBOTIC-ASSISTED VAGINECTOMY (da Vinci Surgical System):

The most advanced minimally invasive option, robotic assistance provides 3D high-definition magnification, EndoWrist® articulation enabling 540° instrument rotation, and tremor filtration — critical advantages in the narrow pelvis. ICG fluorescence can be activated intraoperatively via the Firefly® imaging system for real-time sentinel lymph node mapping. Robotic vaginectomy with nerve-sparing dissection reduces injury to the hypogastric nerves, improving post-operative bladder and bowel function. Studies report significantly lower estimated blood loss (mean 80–150 mL), shorter catheterisation time, and equivalent oncologic margins compared to open surgery. Available at select JCI-accredited centres in Mumbai, Delhi NCR, Chennai, Dubai, and Abu Dhabi partnered with GAF Healthcare.

VAGINAL (PERINEAL) APPROACH:

For lower-third vaginal lesions or gender-affirming colpectomy, an exclusively perineal dissection — sometimes combined with a perineoplasty — is employed. This avoids abdominal incisions entirely, reduces recovery time to 2–3 weeks, and carries lower risk of intra-abdominal adhesion formation. An Abbe-McIndoe split-thickness skin graft neovagina may be created simultaneously if preservation of a vaginal canal is desired.

SENTINEL LYMPH NODE BIOPSY WITH ICG FLUORESCENCE:

Intraoperative injection of ICG dye near the vaginal tumour, visualised under near-infrared fluorescence, identifies the first-echelon draining lymph nodes. This technique — validated in vulvar and cervical cancer — is increasingly applied in early vaginal cancer to spare patients full inguino-femoral or obturator lymphadenectomy, thereby dramatically reducing lower-limb lymphoedema risk.

NEOVAGINA RECONSTRUCTION OPTIONS (where applicable):

• McIndoe technique: Split-thickness skin graft over a vaginal mould; outpatient dilation regimen for 6–12 months post-operatively.

• Sigmoid colon vaginoplasty: Segment of sigmoid colon (15–20 cm) isolated on its mesenteric blood supply; provides a self-lubricating neovagina; preferred in total pelvic exenteration.

• Gracilis myocutaneous flap: Bilateral or unilateral flap from the medial thigh; used when perineal skin is compromised by prior radiation.

• Peritoneal pull-through (Davydov procedure): Pelvic peritoneum mobilised and sutured to the introitus; shorter operative time, no donor-site morbidity.

PHASE 1 — REMOTE CONSULTATION & PRE-OPERATIVE WORKUP (Weeks 1–3 before travel): Patients upload existing biopsy reports, MRI/PET-CT images, and operative notes (if prior surgery) to GAF Healthcare's secure portal. A dedicated medical coordinator allocates a senior gynaecologic oncologist or pelvic surgeon at the partner hospital. A teleconsultation (video call, typically 30–45 minutes) is conducted; the surgeon reviews imaging, confirms candidacy, defines the surgical approach, and prescribes any bridging therapy. Pre-operative labs (CBC, coagulation, renal/liver panel, HbA1c, ECG, 2D ECHO) are performed locally and shared digitally. GAF Healthcare initiates the e-Medical Visa application for India (typically approved in 2–4 business days) or confirms UAE entry visa requirements.

PHASE 2 — ARRIVAL & FINAL PRE-OPERATIVE ASSESSMENT (Days 1–2 in country): Airport pick-up by GAF Healthcare's dedicated driver. Check-in to hospital or partner accommodation. On Day 1: in-hospital pre-anaesthesia assessment, repeat bloods, chest X-ray, consent documentation, and meeting with the surgical team and anaesthesiologist. Bowel preparation is commenced the evening before surgery for procedures involving posterior dissection. Prophylactic low-molecular-weight heparin (LMWH — enoxaparin 40 mg SC) is initiated per VTE prophylaxis protocol. Nil-by-mouth from midnight before surgery.

PHASE 3 — SURGICAL DAY (Day 3): Surgery is performed under general anaesthesia (total intravenous anaesthesia — TIVA — with propofol/remifentanil, or balanced volatile technique). Duration: 2–5 hours depending on extent of resection and reconstruction. Intraoperative cell salvage is available at high-volume centres for complex open cases. A urinary catheter is placed intraoperatively and remains in situ for 5–7 days (longer if bladder dissection was required). Patient is transferred to the high-dependency unit (HDU) or ICU overnight for monitoring if an open or reconstructive procedure was performed; robotic/laparoscopic cases typically recover in standard post-anaesthesia care unit (PACU) and return to the ward within 4–6 hours.

PHASE 4 — EARLY INPATIENT RECOVERY (Days 3–10): Pain management: multimodal analgesia using a patient-controlled epidural (for open cases) or IV/oral NSAIDs and opioid-sparing regimens (for minimally invasive cases). Physiotherapy commences on Day 1 post-op: deep breathing exercises, calf pumps, and — from Day 2 — assisted ambulation. Diet: clear fluids from Day 1, progressing to full diet by Day 3–4 once bowel sounds return. Drain(s) removed when output is less than 30 mL/24 hours (typically Day 3–5). Catheter trial of void at Day 5–7. Wound check and histopathology of resected specimen (margins, lymph node status) reviewed with the patient before discharge.

PHASE 5 — POST-DISCHARGE & IN-COUNTRY RECOVERY (Weeks 2–4 in country): Patients stay in GAF Healthcare's partner serviced apartments or hotel accommodation near the hospital. A follow-up outpatient visit occurs at Day 10–14: wound inspection, staple/suture removal, review of final histopathology and margin status, and discussion of adjuvant therapy (radiation or chemotherapy) if indicated. Pelvic floor physiotherapy and neovagina dilation instructions (if applicable) are provided. Thromboprophylaxis (LMWH or oral rivaroxaban) continues for 4 weeks post-operatively per oncologic surgery VTE guidelines.

PHASE 6 — FIT-TO-FLY CLEARANCE & DEPARTURE (Weeks 4–6): Surgeon clearance for air travel requires: healed surgical wound, no signs of infection or haematoma, confirmed DVT-free status (clinical assessment; Doppler ultrasound if clinically indicated), satisfactory voiding function, and stable haemoglobin. For oncologic cases, the multidisciplinary team (MDT) letter summarising pathology, margin status, and adjuvant therapy recommendations is provided to the patient for their home oncologist. GAF Healthcare coordinates compression stocking provision, in-flight hydration guidance, and aisle seat pre-booking for the return journey. Remote follow-up via teleconsultation is scheduled at 6 weeks, 3 months, and 6 months post-surgery.